Dengue: A continuing global threat

Nature Reviews Microbiology

Volumn 8, Issue 12, 2010, Pages S7-S16

  Guzman, Maria G ^a   Halstead, Scott B ^b   Artsob, Harvey ^c   Buchy, Philippe ^d   Farrar, Jeremy ^e   Gubler, Duane J ^f   Hunsperger, Elizabeth ^g   Kroeger, Axel ^h   Margolis, Harold S ^g   Martí nez, Eric ^a   Nathan, Michael B ^h   Pelegrino, Jose Luis ^a   Simmons, Cameron ^e   Yoksan, Sutee ⁱ   Peeling, Rosanna W ^j  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^b Pediatric Dengue Vaccine Initiative   (South Korea)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^e OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (Puerto Rico)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ MAHIDOL UNIVERSITY   (Thailand)

^j LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE; DENGUE VIRUS; HOSPITALIZATION; HUMAN; INSECT CONTROL; ISOLATION AND PURIFICATION; METHODOLOGY; PACIFIC ISLANDS; REVIEW; SOUTHEAST ASIA; STATISTICS; WESTERN HEMISPHERE;

AMERICAS; ASIA, SOUTHEASTERN; DENGUE; DENGUE VIRUS; HOSPITALIZATION; HUMANS; INSECT CONTROL; PACIFIC ISLANDS;

EID: 79955602230     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro2460     Document Type: Article

References (141)

1. WHO. Scientific Working Group Report on Dengue [online] (WHO, Geneva, Switzerland, 2007).
2. TDR/WHO. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control (TDR/WHO, Geneva, Switzerland, 2009).
3. Guzman, M. G. & Kouri, G. Dengue: an update. Lancet Infect. Dis. 2, 33–42 (2002).
4. Gubler, D. J. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? Comp. Immunol. Microbiol. Infect. Dis. 27, 319–330 (2004).
5. Franco, L. et al. Recent expansion of dengue virus serotype 3 in West Africa. Euro Surveill. 15, 9ii=19490 (2010).
6. Wilder-Smith, A. Dengue in travelers. New Engl. J. Med. 353, 924–932 (2005).
7. Freedman, D. O. et al. Spectrum of disease and relation to place of exposure among ill returned travelers. New Engl. J. Med. 354, 119–130 (2006).
8. Wichmann, O. Dengue antibody prevalence in German travelers. Emerg. Infect. Dis. 11, 762–765 (2005).
9. Jelinek, T. Dengue fever in international travelers. Clin. Infect. Dis. 31, 144–147 (2000).
10. Gubler, D. J. & Meltzer, M. Impact of dengue/dengue hemorrhagic fever on the developing world. Adv. Virus Res. 53, 35–70 (1999).
11. Rodriguez-Roche, R. et al. Virus evolution during a severe dengue epidemic in Cuba, 1997. Virology 334, 154–159 (2005).
12. Wang, E. et al. Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J. Virol. 74, 3227–3234 (2000).
13. Halstead, S. B. Dengue virus–mosquito interactions. Annu. Rev. Entomol. 53, 273–291 (2008).
14. Watts, D. M., Burke, D. S., Harrison, B. A., Whitmire, R. E. & Nisalak, A. Effect of temperature on the vector efficiency of Aedes aegypti for dengue 2 virus. Am. J. Trop. Med. Hyg. 36, 143–152 (1987).
15. Schneider, B. S., Soong, L., Zeidner, N. S. & Higgs, S. Aedes aegypti salivary gland extracts modulate antiviral and TH1/TH2 cytokine responses to Sindbis virus infection. Viral Immunol. 17, 565–573 (2004).
16. Wu, S. J. et al. Human skin Langerhans cells are targets of dengue virus infection. Nature Med. 6, 816–820 (2000).
17. Jessie, K., Fong, M. Y., Devi, S., Lam, S. K. & Wong, K. T. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J. Infect. Dis. 189, 1411–1418 (2004).
18. Halstead, S. B. & O’Rourke, E. J. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non‑neutralizing antibody. J. Exp. Med. 146, 201–217 (1977).
19. Halstead, S. B. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J. Infect. Dis. 140, 527–533 (1979).
20. Goncalvez, A. P., Engle, R. E., St Claire, M., Purcell, R. H. & Lai, C. J. Monoclonal antibodymediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl Acad. Sci. USA 104, 9422–9427 (2007).
21. Kliks, S. C., Nimmanitya, S., Nisalak, A. & Burke, D. S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38, 411–419 (1988).
22. Cummings, D. A. T., Schwartz, I. B., Billings, L., Shaw, L. B. & Burke, D. S. Dynamic effects of antibody‑dependent enhancement on the fitness of viruses. Proc. Natl Acad. Sci. USA 102, 15259–15264 (2005).
23. Guzman, M. G. et al. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am. J. Trop. Med. Hyg. 42, 179–184 (1990).
24. Guzman, M. G. et al. Epidemiologic studies on Dengue in Santiago de Cuba, 1997. Am. J. Epidemiol. 152, 793–799; discussion 804 (2000).
25. Alvarez, M. et al. Dengue hemorrhagic fever caused by sequential dengue 1–3 virus infections over a long time interval: Havana epidemic, 2001–2002 Am. J. Trop. Med. Hyg. 75, 1113–1117 (2006).
26. Guzman, M. G. et al. Effect of age on outcome of secondary dengue 2 infections. Int. J. Infect. Dis. 6, 118–124 (2002).
27. Gamble, J. et al. Age‑related changes in microvascular permeability: a significant factor in the susceptibility of children to shock? Clin. Sci. 98, 211–216 (2000).
28. Kouri, G. P., Guzman, M. G. & Bravo, J. R. Why dengue haemorrhagic fever in Cuba? 2. An integral analysis. Trans. R. Soc. Trop. Med. Hyg. 81, 821–823 (1987).
29. Halstead, S. B., Nimmannitya, S. & Cohen, S. N. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J. Biol. Med. 42, 311–328 (1970).
30. Lee, M. S., Hwang, K. P., Chen, T. C., Lu, P. L. & Chen, T. P. Clinical characteristics of dengue and dengue hemorrhagic fever in a medical center of southern Taiwan during the 2002 epidemic. J. Microbiol. Immunol. Infect. 39, 121–129 (2006).
31. Stephens, H. A. et al. HLA‑A and ‑B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens 60, 309–318 (2002).
32. LaFleur, C. et al. HLA‑DR antigen frequencies in Mexican patients with dengue virus infection: HLA‑DR4 as a possible genetic resistance factor for dengue hemorrhagic fever. Hum. Immunol. 63, 1039–1044 (2002).
33. Loke, H. et al. Strong HLA class I‑restricted T cell responses in dengue hemorrhagic fever: a doubleedged sword? J. Infect. Dis. 184, 1369–1373 (2001).
34. Sakuntabhai, A. et al. A variant in the CD209 promoter is associated with severity of dengue disease. Nature Genet. 37, 507–513 (2005).
35. Fernandez-Mestre, M. T., Gendzekhadze, K., Rivas-Vetencourt, P. & Layrisse, Z. TNF‑α‑308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients. Tissue Antigens 64, 469–472 (2004).
36. Kalayanarooj, S. et al. Blood group AB is associated with increased risk for severe dengue disease in secondary infections. J. Infect. Dis. 195, 1014–1017 (2007).
37. Bravo, J. R., Guzman, M. G. & Kouri, G. P. Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans. R. Soc. Trop. Med. Hyg. 81, 816–820 (1987).
38. Thisyakorn, U. & Nimmannitya, S. Nutritional status of children with dengue hemorrhagic fever. Clin. Infect. Dis. 16, 295–297 (1993).
39. Loke, H. et al. Susceptibility to dengue hemorrhagic fever in vietnam: evidence of an association with variation in the vitamin D receptor and Fc gamma receptor IIa genes. Am. J. Trop. Med. Hyg. 67, 102–106 (2002).
40. Sierra, B. D. et al. Ethnicity and difference in dengue virus‑specific memory T cell responses in Cuban individuals. Viral Immunol. 19, 662–668 (2006).
41. Sierra, B. D., Kouri, G. & Guzman, M. G. Race: a risk factor for dengue hemorrhagic fever. Arch. Virol. 152, 533–534 (2007).
42. Halstead, S. B. et al. Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am. J. Trop. Med. Hyg. 65, 180–183 (2001).
43. Guzman, M. G., Kouri, G. & Halstead, S. B. Do escape mutants explain rapid increases in dengue casefatality rates within epidemics? Lancet 355, 1902–1903 (2000).
44. Guzman, M. G. et al. Enhanced severity of secondary dengue‑2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev. Panam. Salud Pública. 11, 223–227 (2002).
45. Chareonsirisuthigul, T., Kalayanarooj, S. & Ubol, S. Dengue virus (DENV) antibody‑dependent enhancement of infection upregulates the production of anti‑inflammatory cytokines, but suppresses anti‑DENV free radical and pro‑inflammatory cytokine production, in THP‑1 cells. J. Gen. Virol. 88, 365–375 (2007).
46. Simmons, C. P. et al. Patterns of host genome‑wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J. Infect. Dis. 195, 1097–1107 (2007).
47. Couvelard, A. et al. Report of a fatal case of dengue infection with hepatitis: demonstration of dengue antigens in hepatocytes and liver apoptosis. Hum. Pathol. 30, 1106–1110 (1999).
48. Alcon-LePoder, S. et al. The secreted form of dengue virus nonstructural protein NS1 is endocytosed by hepatocytes and accumulates in late endosomes: implications for viral infectivity. J. Virol. 79, 11403–11411 (2005).
49. Malasit, P. Complement and dengue haemorrhagic fever/shock syndrome. Southeast Asian J. Trop. Med. Pub. Health 18, 316–320 (1987).
50. Avirutnan, P. et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J. Infect. Dis. 193, 1078–1088 (2006).
51. Mongkolsapaya, J. et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nature Med. 9, 921–927 (2003).
52. RicoHesse, R. Microevolution and virulence of dengue viruses. Adv. Virus Res. 59, 315–341 (2003).
53. Lin, C. F., Wan, S. W., Cheng, H. J., Lei, H. Y. & Lin, Y. S. Autoimmune pathogenesis in dengue virus infection. Viral Immunol. 19, 127–132 (2006).
54. TDR/WHO. In Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. 23–55 (TDR/WHO, Geneva, Switzerland, 2009).
55. PAHO. Dengue and Dengue Hemorrhagic Fever in the Americas: Guidelines for Prevention and Control. (Pan American Health Organization, Washington, DC, USA 1994).
56. Nimmannitya, S. Clinical spectrum and management of dengue haemorrhagic fever. Southeast Asian J. Trop. Med. Pub. Health 18, 392–397 (1987).
57. Martinez Torres, E. Preventing deaths from dengue: a space and challenge for primary health care. Rev. Panam. Salud Pública 20, 60–74 (2006).
58. Bandyopadhyay, S., Lum, L. C. & Kroeger, A. Classifying dengue: a review of the difficulties in using the WHO case classification for dengue haemorrhagic fever. Trop. Med. Int. Health 11, 1238–1255 (2006).
59. Rigau-Perez, J. G. Severe dengue: the need for new case definitions. Lancet Infect. Dis. 6, 297–302 (2006).
60. Deen, J. L. et al. The WHO dengue classification and case definitions: time for a reassessment. Lancet 368, 170–173 (2006).
61. Balmaseda, A. Assessment of the World Health Organization scheme for classification of dengue severity in Nicaragua. Am. J. Trop. Med. Hyg. 73, 1059–1062 (2005).
62. Thangaratham, P. S. & Tyagi, B. K. Indian perspective on the need for new case definitions of severe dengue. Lancet Infect. Dis. 7, 81–82 (2007).
63. Vorndam, V. & Kuno, G. In Dengue and Dengue Hemorrhagic Fever (eds Gubler, D. J. & Kuno, G.) 313–333 (CAB International, New York, USA, 1997).
64. Guzman, M. G. & Kouri, G. Dengue diagnosis, advances and challenges. Int. J. Infect. Dis. 8, 69–80 (2004).
65. Innis, B. L. et al. An enzyme‑linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co‑circulate. Am. J. Trop. Med. Hyg. 40, 418–427 (1989).
66. Chanama, S. et al. Analysis of specific IgM responses in secondary dengue virus infections: levels and positive rates in comparison with primary infections. J. Clin. Virol. 31, 185–189 (2004).
67. Gubler, D. J. Serologic diagnosis of dengue/dengue haemorrhagic fever. Dengue Bull. 20, 20–23 (1996).
68. Vazquez, S. et al. Kinetics of antibodies in sera, saliva, and urine samples from adult patients with primary or secondary dengue 3 virus infections. Int. J. Infect. Dis. 11, 256–262 (2007).
69. Halstead, S. B., Rojanasuphot, S. & Sangkawibha, N. Original antigenic sin in dengue. Am. J. Trop. Med. Hyg. 32, 154–156 (1983).
70. Singh, K. R. P. & Paul, S. D. Multiplication of arboviruses in cell lines from Aedes albopictus and Aedes aegypti. Curr. Sci. 37, 65–67 (1968).
71. Race, M. W., Williams, M. C. & Agostini, C. F. Dengue in the Caribbean: virus isolation in a mosquito (Aedes pseudoscutellaris) cell line. Trans. R. Soc. Trop. Med. Hyg. 73, 18–22 (1979).
72. Henchal, E. A., McCown, J. M., Seguin, M. C., Gentry, M. K. & Brandt, W. E. Rapid identification of dengue virus isolates by using monoclonal antibodies in an indirect immunofluorescence assay. Am. J. Trop. Med. Hyg. 32, 164–169 (1983).
73. Kao, C. L. et al. Flow cytometry compared with indirect immunofluorescence for rapid detection of dengue virus type 1 after amplification in tissue culture. Clin. Microbiol. 39, 3672–3677 (2001).
74. Guzman, M. G. et al. Fatal dengue hemorrhagic fever in Cuba, 1997. Int. J. Infect. Dis. 3, 130–135 (1999).
75. Rosen, L., Drouet, M. T. & Deubel, V. Detection of dengue virus RNA by reverse transcription‑polymerase chain reaction in the liver and lymphoid organs but not in the brain in fatal human infection. Am. J. Trop. Med. Hyg. 61, 720–724 (1999).
76. Cardosa, M. J., Tio, P. H., Nimmannitya, S., Nisalak, A. & Innis, B. IgM capture ELISA for detection of IgM antibodies to dengue virus: comparison of 2 formats using hemagglutinins and cell culture derived antigens. Southeast Asian J. Trop. Med. Pub. Health 23, 726–729 (1992).
77. Vazquez, S. et al. Detection of IgM against the dengue virus in whole blood absorbed on filter paper. Rev. Panam. Salud Pública 3, 174–178 (1998).
78. Herrera, R. D., Cabrera, M. V., Garcia, S. & Gilart, M. IgM antibodies to dengue virus in dried blood on filter paper. Clin. Chim. Acta 367, 204–206 (2006).
79. Balmaseda, A. et al. Diagnosis of dengue virus infection by detection of specific immunoglobulin M (IgM) and IgA antibodies in serum and saliva. Clin. Diagn. Lab. Immunol. 10, 317–322 (2003).
80. Blacksell, S. D. et al. The comparative accuracy of 8 commercial rapid immunochromatographic assays for the diagnosis of acute dengue virus infection. Clin. Infect. Dis. 42, 1127–1134 (2006).
81. Blacksell, S. D. et al. Prospective study to determine accuracy of rapid serological assays for diagnosis of acute dengue virus infection in Laos. Clin. Vaccine Immunol. 14, 1458–1464 (2007).
82. Hunsperger, E. A. et al. Evaluation of commercially available anti‑dengue virus immunoglobulin M tests. Emerg. Infect. Dis. 15, 436–440 (2009).
83. Vazquez, S., Bravo, J. R., Perez, A. B. & Guzman, M. G. Inhibition ELISA. Its utility for classifying a case of dengue. Rev. Cubana Med. Trop. 49, 108–112 (1997).
84. Falconar, A. K., de Plata, E. & Romero-Vivas, C. M. Altered enzyme‑linked immunosorbent assay immunoglobulin M (IgM)/IgG optical density ratios can correctly classify all primary or secondary dengue virus infections 1 day after the onset of symptoms, when all of the viruses can be isolated. Clin. Vaccine Immunol. 13, 1044–1051 (2006).
85. Cardosa, M. J., Wang, S. M., Sum, M. S. & Tio, P. H. Antibodies against prM protein distinguish between previous infection with dengue and Japanese encephalitis viruses. BMC Microbiol. 2, 9 (2002).
86. Wong, S. J. et al. Immunoassay targeting nonstructural protein 5 to differentiate west nile virus infection from dengue and St. Louis encephalitis virus infections and from flavivirus vaccination. J. Clin. Microbiol. 41, 4217–4223 (2003).
87. Baretto dos Santos, F. et al. Analysis of recombinant dengue virus polypeptides for dengue diagnosis and evaluation of the humoral immune response. Am. J. Trop. Med. Hyg. 71, 144–152 (2004).
88. Kuno, G., Gomez, I. & Gubler, D. J. An ELISA procedure for the diagnosis of dengue infections. J. Virol. Methods 33, 101–113 (1991).
89. Shu, P. Y. et al. Comparison of capture immunoglobulin M (IgM) and IgG enzyme‑linked immunosorbent assay (ELISA) and nonstructural protein NS1 serotypespecific IgG ELISA for differentiation of primary and secondary dengue virus infections. Clin. Diagn. Lab. Immunol. 10, 622–630 (2003).
90. Calisher, C. H. et al. Antigenic relationships between flaviviruses as determined by cross‑neutralization tests with polyclonal antisera. J. Gen. Virol. 70, 37–43 (1989).
91. Russell, P. K. & Nisalak, A. Dengue virus identification by the plaque reduction neutralization test. J. Immunol. 99, 291–296 (1967).
92. Morens, D. M., Halstead, S. B., Repik, P. M., Putvatana, R. & Raybourne, N. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK‑21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J. Clin. Microbiol. 22, 250–254 (1985).
93. Thomas, S. J. et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am. J. Trop. Med. Hyg. 81, 825–833 (2009).
94. Roehrig, J. T. et al. Guidelines for plaque‑reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 21, 123–132 (2008).
95. Morita, K., Tanaka, M. & Igarashi, A. Rapid identification of dengue virus serotypes by using polymerase chain reaction. J. Clin. Microbiol. 29, 2107–2110 (1991).
96. Lanciotti, R. S., Calisher, C. H., Gubler, D. J., Chang, G. J. & Vorndam, A. V. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase‑polymerase chain reaction. J. Clin. Microbiol. 30, 545–551 (1992).
97. Harris, E. et al. Typing of dengue viruses in clinical specimens and mosquitoes by single‑tube multiplex reverse transcriptase PCR. J. Clin. Microbiol. 36, 2634–2639 (1998).
98. Raengsakulrach, B. et al. Comparison of four reverse transcription‑polymerase chain reaction procedures for the detection of dengue virus in clinical specimens. J. Virol. Methods 105, 219–232 (2002).
99. Johnson, B. W., Russell, B. J. & Lanciotti, R. S. Serotype‑specific detection of dengue viruses in a fourplex real‑time reverse transcriptase PCR assay. J. Clin. Microbiol. 43, 4977–4983 (2005).
100. Chien, L. J. et al. Development of real‑time reverse transcriptase PCR assays to detect and serotype dengue viruses. J. Clin. Microbiol. 44, 1295–1304 (2006).
101. Kong, Y. Y., Thay, C. H., Tin, T. C. & Devi, S. Rapid detection, serotyping and quantification of dengue viruses by TaqMan real‑time one‑step RT‑PCR. J. Virol. Methods 138, 123–130 (2006).
102. Vaughn, D. W. et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181, 2–9 (2000).
103. Wu, S. J. et al. Detection of dengue viral RNA using a nucleic acid sequence‑based amplification assay. J. Clin. Microbiol. 39, 2794–2798 (2001).
104. Hall, W. C. et al. Demonstration of yellow fever and dengue antigens in formalin‑fixed paraffin‑embedded human liver by immunohistochemical analysis. Am. J. Trop. Med. Hyg. 45, 408–417 (1991).
105. Pelegrino, J. L. et al. Standardization of immunohistochemical techniques for detecting dengue virus antigens in paraffin‑embedded tissues. Rev. Cubana Med. Trop. 49, 100–107 (1997).
106. Limonta, D., Capo, V., Torres, G., Perez, A. B. & Guzman, M. G. Apoptosis in tissues from fatal dengue shock syndrome. J. Clin. Virol. 40, 50–54 (2007).
107. Shu, P. Y. et al. Potential application of nonstructural protein NS1 serotype‑specific immunoglobulin G. enzyme‑linked immunosorbent assay in the seroepidemiologic study of dengue virus infection: correlation of results with those of the plaque reduction neutralization test. J. Clin. Microbiol. 40, 1840–1844 (2002).
108. Xu, H. et al. Serotype 1‑specific monoclonal antibodybased antigen capture immunoassay for detection of circulating nonstructural protein NS1: implications for early diagnosis and serotyping of dengue virus infections. J. Clin. Microbiol. 44, 2872–2878 (2006).
109. Young, P. R., Hilditch, P. A., Bletchly, C. & Halloran, W. An antigen capture enzyme‑linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. J. Clin. Microbiol. 38, 1053–1057 (2000).
110. WHO. Scientific working group on dengue. Meeting Report 3–5 April, 2000 [online] (WHO, Geneva, Switzerland, 2000).
111. WHO. Dengue fever and dengue haemorrhagic fever prevention and control. World Health Assembly Resolution WHA55.17, adopted by the 55th World Health Assembly [online] (WHO, Geneva, Switzerland, 2002).
112. WHO. Revision of the International Health Regulations. World Health Assembly Resolution WHA58.3, adopted by the 58th World Health Assembly [online] (WHO, Geneva, Switzerland, 2005).
113. TDR/WHO. In Dengue Guidelines for Diagnosis, Treatment, Prevention and Control. 111–133 (TDR/WHO, Geneva, Switzerland, 2009).
114. Rodriguez, M. M., Bisset, J. A. & Fernandez, D. Levels of insecticide resistance and resistance mechanisms in Aedes aegypti from some Latin American countries. J. Am. Mosq. Control Assoc. 23, 420–429 (2007).
115. Brengues, C. et al. Pyrethroid and DDT crossresistance in Aedes aegypti is correlated with novel mutations in the voltage‑gated sodium channel gene. Med. Vet. Entomol. 17, 87–94 (2003).
116. Nam, V. S., Yen, N. T., Holynska, M., Reid, J. W. & Kay, B. H. National progress in dengue vector control in Vietnam: survey for Mesocyclops (Copepoda), Micronecta (Corixidae), and fish as biological control agents. Am. J. Trop. Med. Hyg. 62, 5–10 (2000).
117. Kay, B. H. et al. Control of Aedes vectors of dengue in three provinces of Vietnam by use of Mesocyclops (Copepoda) and community‑based methods validated by entomologic, clinical, and serological surveillance. Am. J. Trop. Med. Hyg. 66, 40–48 (2002).
118. Focks, D. A. & Alexander, N. Multicountry study of Aedes aegypti pupal productivity survey methodology: findings and recommendations [online] (WHO/TDR, Geneva, Switzerland, 2006).
119. Heintze, C., Garrido, M. V. & Kroeger, A. What do community‑based dengue control programmes achieve? A systematic review of published evaluations. Trans. R. Soc. Trop. Med. Hyg. 101, 317–325 (2007).
120. Kroeger, A. et al. Effective control of dengue vectors with curtains and water container covers treated with insecticide in Mexico and Venezuela: cluster randomized trials. Br. Med. J. 332, 1247–1252 (2006).
121. Mulla, M. S., Thavara, U., Tawatsin, A., Kong-Ngamsuk, W. & Chompoosri, J. Mosquito burden and impact on the poor: measures and costs for personal protection in some communities. J. Am. Mosq. Control Assoc. 17, 153–159 (2001).
122. Hombach, J. Vaccines against dengue: a review of current candidate vaccines at advanced development stages. Rev. Panam. Salud Pública 21, 254–260 (2007).
123. Hombach J., Cardosa J. M., Sabchareon, A., Vaughn, D. W. & Barrett, A. D. T. Scientific consultation on immunological correlates of protection induced by dengue vaccines. Report from a meeting held at the World Health Organization 17–18 November 2005. Vaccine 25, 4130–4139 (2007).
124. Bettramello, M. et al. The human immune response to dengue virus is dominated by highly cross‑reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8, 271–283 (2010).
125. Dejnirattisai, W. et al. Cross‑reacting antibodies enhance dengue virus infection in humans. Science 328, 745–748 (2010).
126. Whitehead, S. S., Blaney, J. E., Durbin, A. P. & Murphy, B. R. Prospects for a dengue virus vaccine. Nature Rev. Microbiol. 5, 518–528 (2007).
127. Rothman, A. L. Dengue: defining protective versus pathologic immunity. J. Clin. Invest. 113, 946–951 (2004).
128. Halstead, S. B., Heinz, F. X., Barrett, A. D. & Roehrig, J. T. Dengue virus: molecular basis of cell entry and pathogenesis. Vaccine 23, 849–856 (2005).
129. Guirakhoo, F. et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax‑DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre‑immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccine 2, 60–67 (2006).
130. Durbin, A. P. et al. rDEN4 Delta 30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J. Infect. Dis. 191, 710–718 (2005).
131. Raviprakash, K. et al. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 353, 166–173 (2006).
132. Hermida, L. et al. A recombinant fusion protein containing the domain III of the dengue‑2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24, 3165–3171 (2006).
133. Whitehead, S. S. et al. A live, attenuated dengue virus type 1 vaccine candidate with a 30‑nucleotide deletion in the 3 untranslated region is highly attenuated and immunogenic in monkeys. J. Virol. 77, 1653–1657 (2003).
134. Edelman, R. et al. Phase I trial of 16 formulations of a tetravalent live‑attenuated dengue vaccine. Am. J. Trop. Med. Hyg. 69, 48–60 (2003).
135. Wright, P. F. et al. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4Δ30‑4995 in healthy adult volunteers. Am. J. Trop. Med. Hyg. 81, 834–841 (2009).
136. Morrison, D. et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus‑naive adults. J. Infect. Dis. 201, 370–377 (2010).
137. WHO. Pocket book of hospital care for children. Guidelines for the management of common illnesses with limited resources [online] (WHO, Geneva, Switzerland, 2005).
138. WHO. Dengue haemorrhagic fever: early recognition, diagnosis and hospital management. An audiovisual guide for health‑care workers responding to outbreaks [online] WHO, Geneva, Switzerland, 2006).
139. Parks, W. & Lloyd, L. Planning social mobilization and communication for dengue fever prevention and control: a step‑by‑step guide [online] (WHO, Geneva, Switzerland, 2004).
140. WHO. Global strategic framework for integrated vector management [online] http://whqlibdoc.who.int/hq/2004/WHO_CDS_CPE_PVC_2004_10.pdf (WHO, Geneva, Switzerland, 2004).
141. Gubler, D. J. Dengue and dengue haemorrhagic fever. Clin. Microbiol. Rev. 11, 480–496 (1998).